GPP
PHAT icon

Great Point Partners’s Phathom Pharmaceuticals PHAT Stock Holding History

Great Point Partners’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-220,863
Closed -$7.09M – 46
2021
Q3 		$7.09M Buy
+220,863
New +$7.34M 1.65% 28

Other funds holding PHAT

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Great Point Partners's PHAT Position: Q4 2021 in Review

Great Point Partners sold out of Phathom Pharmaceuticals (PHAT) in Q4 2021, closing a stake of 220,863 shares — an estimated $7.09M sold.

Great Point Partners first reported a position in PHAT in Q3 2021 and held it in 1 quarter. The position peaked at $7.09M in Q3 2021. 83 funds tracked by Wall St. Rank hold PHAT as of Q4 2021.

  • Great Point Partners reported no remaining Phathom Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Great Point Partners sold 220,863 Phathom Pharmaceuticals shares in Q4 2021, an estimated $7.09M.
  • Great Point Partners first reported a position in Phathom Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Great Point Partners's Phathom Pharmaceuticals position peaked at $7.09M in Q3 2021.
  • 83 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q4 2021.

Based on Great Point Partners's 13F filing for Q4 2021, filed 14 Feb 2022.